Sunday 18 October 2026
Export DYNTQ’s income statement to Excel — free account
Dynatronics Corporation
DYNTQ Healthcare Medical Devices
Dynatronics Corporation’s revenue for fiscal 2025 (year ended June 2025) was $27.4 million, down 15.8% from fiscal 2024. In the quarter to September 2025, revenue fell 7.61%, EPS grew 66.7% and free cash flow fell 193.0%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow DYNTQ
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.03 | 0.03 | 0.02 | 0.03 | |
P/FCF ratio |
0.00 | 2.10 | 2.43 | 12.01 | |
P/Operating CF |
6.49 | (48.58) | 7.74 | (9.78) | |
P/B ratio |
0.17 | 0.22 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.12 | 0.13 | 0.12 | 0.14 | |
EV/EBITDA |
0.00 | 0.00 | 0.60 | 0.66 | |
EV/Operating CF |
24.76 | 8.02 | 11.24 | 34.96 | |
EV/FCF |
(50.62) | 8.84 | 12.61 | 49.08 | |
Quick Ratio |
0.42 | 0.40 | 0.41 | 0.43 | |
Current Ratio |
1.21 | 1.15 | 1.09 | 1.07 | |
Net Debt/EBITDA |
(6.33) | (3.91) | 0.40 | 32.73 | |
Debt/Assets |
14.07% | 12.97% | 20.11% | 24.19% | |
Debt/Equity |
0.28 | 0.25 | 0.95 | 1.19 | |
Asset Turnover |
1.09 | 1.11 | 1.32 | 1.34 | |
Operating CF/Net income |
(0.14) | 0.02 | (0.01) | 0.24 | |
Capex/Depreciation |
(0.05) | (0.09) | 0.00 | 0.00 | |
Interest Coverage |
(6.15) | (9.90) | (5.92) | (0.86) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
31.66% | 33.17% | 29.67% | 25.91% | |
Intangible Assets out of Total Assets |
0.38 | 0.41 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
0.02% | 0.01% | 0.01% | 0.00% | |
Graham Net Nets |
(1.89) | (2.36) | (4.96) | (3.21) | |
Graham Number |
0.00 | 0.00 | 4.29 | 3.39 | |
Earnings Yield |
(616.75%) | (700.10%) | (1,762.50%) | (1,928.57%) | |
Free Cash Flow Yield |
(8.29%) | 47.53% | 41.20% | 8.33% | |
Revenue per Share |
1.01 | 0.70 | 0.78 | 0.54 | |
Operating CF per Share |
0.02 | 0.00 | 0.01 | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.02 | 0.00 | 0.01 | (0.01) | |
Cash per Share |
0.12 | 0.03 | 0.05 | 0.06 | |
Shareholders Equity per Share |
1.79 | 1.37 | 0.40 | 0.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.79 | 1.37 | 0.40 | 0.23 | |
Free Cash Flow |
0.12 | (0.04) | 0.08 | (0.09) | |
Working Capital |
1.89 | 1.19 | 0.72 | 0.59 | |
Capital Expenditures |
(0.01) | (0.02) | 0.00 | 0.00 | |
Net Current Asset Value |
(1.64) | (2.07) | (3.22) | (2.93) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.63 | 3.61 | 3.44 | 3.17 | |
Average Payables |
3.72 | 3.64 | 3.06 | 2.95 | |
Average Inventory |
6.65 | 5.83 | 5.33 | 5.15 | |
Average Assets |
27.53 | 25.61 | 20.69 | 20.03 | |
Average Common Equity |
6.29 | 5.45 | 0.73 | 0.45 |
Columns are period end dates